Biotechnology in Healthcare
🌟 Introduction: Why Does This Chapter Matter?
Imagine two patients suffering from the same disease — say, cancer. One is given a standard chemical drug that kills cancer cells but also destroys healthy tissue along the way. The other receives a precisely engineered biological molecule that hunts down only the cancer cells like a guided missile and leaves healthy cells untouched. This is the power of Biotechnology in Healthcare.
From the insulin that keeps millions of diabetics alive, to vaccines that eradicated smallpox from the face of the earth, to CAR-T cell therapy that is literally reprogramming a patient’s own immune cells to fight cancer — biotechnology has transformed modern medicine. For UPSC, this chapter is a goldmine of both Prelims MCQs and Mains essay material. Let us understand it, not just memorize it.
Biopharmaceuticals (Biologics)
Think of conventional medicines — paracetamol, aspirin — as small, simple molecules made in a chemistry lab. Now imagine medicines that are produced not in a lab with chemicals, but inside living cells — bacteria, yeast, or mammalian cells. These are Biopharmaceuticals, also called Biologics. They are large, complex molecules — primarily proteins — designed to treat, diagnose, or prevent diseases.
Types include: Therapeutic Proteins, Monoclonal Antibodies (mAbs), Vaccines, Gene Therapy, and Cell-Based Therapies.
Key Characteristics
- Biotechnology-based production: Made using Recombinant DNA technology, genetic engineering, and cell culture systems.
- Large & complex molecules: Primarily proteins, peptides, nucleic acids, or living cells — far more complex than conventional drugs.
- High target specificity: Acts precisely on specific cells, receptors, or molecular pathways — like a sniper vs. a shotgun.
- Parenteral administration: Usually injected or infused because digestive enzymes would break them down if taken orally.
Biopharmaceuticals vs. Conventional Drugs
This comparison is a favourite in UPSC. Study this table carefully.
| Feature | Biopharmaceuticals (Biologics) | Conventional Drugs |
| Definition | Produced using living organisms & biotechnology | Produced through chemical synthesis |
| Molecular Nature | Large & complex (proteins, antibodies, nucleic acids) | Small, relatively simple chemical molecules |
| Production Method | Recombinant DNA tech, cell culture, biotechnology | Chemical reactions in labs/pharma factories |
| Source | Living cells — bacteria, yeast, mammalian cells | Synthetic chemicals or modified natural compounds |
| Target Specificity | Highly specific — targets particular cells/molecules | Less specific — may affect multiple pathways |
| Administration | Injected/infused (degraded by digestion) | Often oral — tablets or capsules |
| Manufacturing Cost | Complex & expensive | Relatively simpler & cheaper |
| Stability | Temperature-sensitive — requires cold chain | More stable, easier to store |
| Examples | Insulin, monoclonal antibodies, vaccines | Aspirin, paracetamol, antibiotics |
Advantages of Biopharmaceuticals
- Effective for complex diseases: Cancers, autoimmune disorders, genetic diseases that conventional drugs cannot tackle well.
- Reduced side effects: Targeted action means less damage to healthy tissues.
- Support personalised medicine: Can be developed based on a patient’s genetic or molecular profile.
- Reduced toxicity: Similar to naturally occurring human molecules — fewer adverse reactions.
- Improved outcomes: High specificity and biological compatibility lead to better efficacy in chronic/life-threatening diseases.
Disadvantages of Biopharmaceuticals
- High cost: Advanced biotech, complex research & specialised manufacturing make them expensive.
- Complex manufacturing: Living cells and sophisticated techniques make production complicated.
- Stability issues: Temperature-sensitive; require cold chain logistics.
- Limited administration routes: Cannot be taken orally — require injection or infusion.
- Shorter shelf life: Proteins are less stable than small-molecule drugs.
- Risk of immune reactions: The body may recognise them as foreign and mount an immune response.
Therapeutic Proteins
Imagine the human body as a highly sophisticated factory. When one of the machines (proteins) breaks down or is missing, the whole factory suffers. Therapeutic proteins are engineered replacements or supplements for these missing or defective biological machines. They either replace, supplement, or modify biological functions in the body. They are produced using Recombinant DNA technology and cell culture systems.
Major Types of Therapeutic Proteins
1. Replacement Proteins
These replace deficient or missing proteins in the body.
- Insulin: Used for diabetes — the most famous therapeutic protein.
- Human Growth Hormone (HGH): For growth hormone deficiency.
2. Cytokines
Proteins that stimulate or regulate the immune system — think of them as the body’s molecular ‘commanders’.
- Interferons: Used in viral infections and certain cancers.
- Interleukins: Regulate immune responses.
3. Enzymes
Therapeutic enzymes replace missing enzymes or help break down harmful substances.
- Alteplase: Dissolves blood clots in heart attacks or strokes.
4. Blood Factors
Proteins for blood clotting (hemostasis) or blood formation (hematopoiesis).
- Erythropoietin (EPO): Stimulates red blood cell production in anaemia.
- Factor VIII: Treatment of haemophilia.
Monoclonal Antibodies (mAbs)
Here is an analogy that will make this concept unforgettable. Think of your immune system as an army. When a foreign invader enters, the army produces antibodies — specific soldiers trained to recognise and neutralise that one particular invader. Monoclonal Antibodies (mAbs) are like a perfectly cloned battalion of identical soldiers — all produced from a single clone of immune cells, all designed to target one specific antigen (target molecule) with pinpoint accuracy.
They are produced using Hybridoma Technology or Recombinant DNA Technology and are widely used in disease diagnosis, treatment, and biomedical research.
Major Medical Applications of mAbs
| Application Area | What mAbs Do | Key Examples |
| Cancer Treatment | Target specific proteins on cancer cells; help immune system destroy them | Rituximab (lymphoma), Trastuzumab (HER2+ breast cancer) |
| Autoimmune Diseases | Suppress abnormal immune responses | Adalimumab (rheumatoid arthritis), Infliximab (Crohn’s disease) |
| Infectious Diseases | Neutralise viruses or toxins | Palivizumab (prevents RSV infection) |
| Diagnostic Applications | Detect specific antigens in tests | Pregnancy tests, disease detection, immunoassays |
| Targeted Drug Delivery | Act as carriers for drugs/toxins/radioactive molecules to diseased cells | Improves precision; reduces damage to healthy tissue |
| Organ Transplantation | Prevent rejection by suppressing specific immune responses | Used post-transplant in organ rejection prevention |
📌 Mnemonic: CAIDO — Cancer, Autoimmune, Infectious, Diagnostic, Organ transplantation — the 5 key applications of mAbs.
Vaccines
If there is one biotechnology achievement that has saved the most human lives, it is the vaccine. Smallpox — a disease that killed an estimated 300 million people in the 20th century — was completely eradicated by 1980 through vaccination. It remains the first and only human disease ever eradicated by vaccines. That single fact tells you everything about the transformative power of vaccines.
A vaccine is a biological preparation that provides active acquired immunity against a specific disease. It contains weakened, killed, or pieces of the pathogen (or its genetic material) — enough to trigger an immune response, but not enough to cause disease.
Basic Components of a Vaccine
| Component | Role | Examples |
| Antigen (Active Component) | The main ingredient — stimulates the immune system to recognise the pathogen | Killed virus, weakened bacteria, mRNA, protein subunit |
| Adjuvants | Boost the immune response to the antigen | Aluminium salts (aluminium hydroxide) |
| Stabilisers | Maintain vaccine effectiveness during storage & transport | Lactose, sucrose, gelatin, proteins |
| Preservatives | Prevent contamination, especially in multi-dose vials | 2-phenoxyethanol |
| Residual Trace Components | Tiny leftover substances from the manufacturing process | Egg proteins (flu vaccine), antibiotics, cell culture materials |
How Do Vaccines Work? (A 3-Step Story)
This is best understood as a story of military training:
STEP 1 MIMIC INFECTION — Vaccine contains harmless antigens that look foreign to your immune system — like a ‘dummy enemy’. Your body sees them as invaders.
↓
STEP 2 TRIGGER IMMUNE RESPONSE — The immune system mobilises — produces antibodies and activates immune cells to ‘fight’ the harmless antigens.
↓
STEP 3 CREATE MEMORY — After clearing the vaccine, the immune system stores ‘memory cells’ — like a soldier who has been trained. If the real pathogen ever invades, the body responds rapidly and destroys it before illness occurs.
Types of Vaccines
This is a very UPSC-relevant table. Know all six types with examples, advantages, and disadvantages.
| Type | What It Contains | Examples | Advantages | Disadvantages |
| Live Attenuated | Weakened live pathogen — can replicate but doesn’t cause disease | BCG (TB), MMR (Measles-Mumps-Rubella), OPV (Oral Polio) | Strong, long-lasting immunity; often lifelong protection | Not safe for immunocompromised/pregnant; needs cold chain |
| Inactivated (Killed) | Pathogen killed by heat or chemicals — cannot replicate | IPV (Injectable Polio), Hepatitis A, Rabies | Safe for immunocompromised; stable and easier to store | Weaker immunity; requires multiple doses/boosters |
| Subunit / Recombinant / Conjugate / Polysaccharide | Specific pieces of the pathogen (protein or sugar) | Hepatitis B, HPV, Pneumococcal, Meningococcal vaccines | Targeted response; fewer side effects; safe for all | Multiple doses needed; less durable immunity |
| Toxoid | Inactivated bacterial toxins | Diphtheria, Tetanus vaccines | Highly effective against toxin-mediated diseases; stable and safe | Requires periodic boosters |
| mRNA / DNA | Genetic material instructing cells to produce harmless pathogen proteins (e.g., spike proteins) | Pfizer, Moderna (COVID-19 mRNA); ZyCoV-D (DNA, Zika trials) | Quick to design; no risk of infection; highly adaptable to new diseases | Ultra-cold storage required (mRNA); long-term data still evolving |
| Viral Vector | Harmless virus (e.g., adenovirus) delivers pathogen protein genes into cells | Covishield (Oxford-AZ), Sputnik V, Johnson & Johnson | Strong immunity — both antibody and T-cell response; some are single-dose | Pre-existing immunity to vector virus may reduce efficacy; mild flu-like side effects |
Importance of Vaccines
- Prevention of deadly diseases: Vaccines protect against 30+ life-threatening diseases. Smallpox was eradicated in 1980 — the FIRST and ONLY human disease ever eradicated by vaccines.
- Reduction in mortality & morbidity: Immunisation currently prevents an estimated 3.5 to 5 million deaths worldwide annually.
- Herd Immunity: When enough people in a population are immune, the disease cannot spread — even protecting the unvaccinated. Key term: Herd immunity = indirect protection of a population through widespread vaccination or natural immunity.
- Control of outbreaks: Vaccines are critical for routine prevention and rapid response to outbreaks, epidemics, and pandemics (COVID-19, Ebola, Measles).
- Economic & social benefits: Lower healthcare costs, higher productivity, reduced poverty, and improved global health equity.
Important Definitions — Outbreak vs. Epidemic vs. Pandemic
| Term | Definition | Scale | Example |
| Outbreak | Sudden increase in disease cases in a localised area | Local / District | Measles in a district |
| Epidemic | Disease spreading rapidly beyond normal expectations in a community/region | Community / Country | Swine flu in India |
| Pandemic | Disease spreading across multiple countries/continents affecting global population | Global | COVID-19 |
Challenges in Vaccine Development
- Pathogen diversity & mutation: Rapidly mutating viruses (HIV, influenza, SARS-CoV-2) challenge long-lasting vaccine development. Antigenic drift and shift demand continuous reformulation (e.g., seasonal flu shots).
- Incomplete immunological understanding: For Malaria, Dengue, or TB, the immune system’s protective response is not fully understood, delaying vaccine innovation.
- One-size-fits-all limitations: Genetic variability, nutritional status, comorbidities, and microbiome differences affect vaccine efficacy across populations.
- Vaccine hesitancy: Fueled by misinformation, religious beliefs, and myths — a major barrier to immunisation (e.g., HPV, COVID-19).
- Cold chain requirements: mRNA, viral vector, and live-attenuated vaccines need storage from -70°C to 2–8°C — challenging in rural/resource-limited areas.
- Booster & multi-dose complexity: DPT, Hepatitis B, and COVID-19 require multiple doses — straining logistics and reducing compliance.
- Lengthy development process: Standard vaccine R&D takes 10–15 years. Emergency-use authorisation (e.g., COVID-19) is an exception, not the norm.
- High R&D costs: Development can cost billions with no guarantee of success.
- Market limitations & neglected diseases: For neglected tropical diseases (Ebola, Nipah), little commercial incentive leads to underinvestment. Public/philanthropic funding (CEPI, Gates Foundation) is essential.
- Inequity in access: LMICs face delays and limited access — starkly seen during COVID-19, leading to the push for COVAX and local manufacturing.
- Ethical concerns: Testing new vaccines on humans requires ethical transparency, informed consent, and strict oversight.
Global Initiatives in Vaccine Development
GAVI — The Vaccine Alliance
GAVI (formerly Global Alliance for Vaccines and Immunisation) is a public-private global health partnership founded in 2000, headquartered in Geneva, Switzerland. It is an alliance of WHO, UNICEF, World Bank, Bill & Melinda Gates Foundation, vaccine manufacturers, research agencies, donor governments, and implementing countries.
- Objective: Increase access to immunisation in LMICs; introduce new vaccines; strengthen health systems; co-finance procurement.
Key Functions of GAVI
- Vaccine funding & procurement: Helps countries buy HPV, pneumococcal, rotavirus, pentavalent, COVID-19 vaccines.
- Health system strengthening: Supports cold chain, logistics, data systems, and training.
- Market shaping: Pools demand from multiple countries to negotiate lower prices and ensure sustainable supply.
- Emergency response: Rapid vaccine financing in outbreaks — Ebola, cholera, COVID-19.
Major Achievements of GAVI
- Immunisation reach: Helped vaccinate over 1 billion children since 2000; averted 17+ million deaths.
- Affordable vaccines: HPV vaccine prices dropped by >90% for GAVI countries through pooled procurement.
- New vaccine programmes: PCV (pneumococcal pneumonia), rotavirus diarrhoea, HPV (cervical cancer).
- COVAX Partnership: With WHO and CEPI, ensured even the poorest nations access COVID-19 vaccines.
GAVI’s Importance for India
- Financial support: Funded pentavalent, rotavirus, and pneumococcal vaccine introduction in India.
- Universal Immunisation Programme (UIP): Major partner in scaling up India’s largest public health initiative.
- Mission Indradhanush: Supported Intensified Mission Indradhanush targeting underserved areas.
- ‘Make in India’: India (Serum Institute, Bharat Biotech) is a major GAVI vaccine supplier — boosting India’s vaccine diplomacy.
WHO Global Vaccine Action Plan (GVAP)
GVAP was launched in 2012 by WHO with UNICEF, GAVI, Gates Foundation, World Bank, endorsed by all 194 WHO member states. It was concluded in 2020.
Vision: All individuals and communities enjoy lives free from vaccine-preventable diseases.
| Aspect | Details |
| Launched | 2012 (concluded 2020) |
| Key Goal | ≥90% national immunisation coverage for all vaccines |
| Other Goals | Eliminate key VPDs; introduce new vaccines; ensure sustainability; promote R&D |
| Achievements | 116+ countries introduced new vaccines; near-elimination of maternal & neonatal tetanus; groundwork for COVID-19 rollout |
| Challenges / Missed Targets | Many countries failed ≥90% immunisation; measles outbreaks due to hesitancy; persistent inequity in access |
Immunisation Agenda 2030 (IA2030)
IA2030 was launched by WHO as the successor to GVAP. It focuses on equity, gender-responsive approaches, pandemic preparedness, digital tools, and country-owned systems.
Targets by 2030
- Vaccinate 90% of children with essential vaccines
- Introduce at least one new/underused vaccine in all countries
- Reduce zero-dose children by 50%
- Fully vaccinate 90% of girls against HPV by age 15
- Reduce global measles incidence by 90%
- Sustain elimination of maternal and neonatal tetanus
- Prevent 50 million deaths through immunisation (2021–2030)
Coalition for Epidemic Preparedness Innovations (CEPI)
- Founded: 2017, after the Ebola crisis.
- Purpose: Funds and accelerates R&D for vaccines against emerging infectious diseases — Nipah, MERS, Lassa fever, Rift Valley fever, Chikungunya, and the hypothetical ‘Disease X’.
- COVID-19: Played a key role in fast-tracking COVID-19 vaccine platforms.
COVAX Facility
- Led by: WHO, GAVI, and CEPI during the COVID-19 pandemic.
- Aim: Ensure fair and equitable global access to COVID-19 vaccines, preventing Vaccine Nationalism.
📌 Vaccine Nationalism: The practice where countries prioritise securing vaccines for their own populations — often by pre-ordering or hoarding supplies — at the expense of equitable global distribution. COVAX was the global counter to vaccine nationalism.
India’s Vaccine Development Achievements
India — The ‘Pharmacy of the World’
India supplies over 60% of global vaccine demand by volume — a staggering statistic. Indian vaccines are the backbone of childhood immunisations, pandemic responses, and affordable healthcare in low-income countries worldwide.
- Serum Institute of India (SII), Pune: The world’s largest vaccine manufacturer by number of doses produced. Supplies to UNICEF, PAHO, GAVI, and global immunisation programmes. Manufactures vaccines for Polio, Measles, Mumps, Rubella, Meningitis, Rotavirus, HPV, Influenza, COVID-19.
Institutions Involved in Vaccine Development in India
| Institution | Role |
| Indian Council of Medical Research (ICMR) | Funds, coordinates, and conducts vaccine R&D across institutes and with private partners |
| Department of Biotechnology (DBT) | Supports cutting-edge biotech platforms for vaccines — DNA, mRNA, and recombinant technologies |
| BIRAC (Biotechnology Industry Research Assistance Council) | DBT public sector arm — provides grants and incubation support to start-ups and SMEs for vaccine innovation |
| National Institute of Virology (NIV), Pune | Premier ICMR institute — leads virus isolation, strain characterisation, and safety testing critical for vaccine design |
Indigenous Vaccine Successes
India has developed some of the world’s most significant vaccines in recent years. Study this table — it is very UPSC relevant.
| Vaccine | Developer | Type | Key Feature |
| Covaxin | Bharat Biotech + ICMR | Inactivated virus | India’s FIRST fully indigenous COVID-19 vaccine |
| Rotavac | Bharat Biotech | Live-attenuated | India’s first indigenous rotavirus vaccine |
| Pneumosil | Serum Institute of India | Pneumococcal conjugate (PCV) | India’s first indigenously developed PCV |
| ZyCoV-D | Zydus Cadila | DNA plasmid-based | World’s FIRST DNA-based human vaccine approved for COVID-19; needle-free |
| GEMCOVAC-OM | Gennova Biopharmaceuticals | mRNA | India’s first indigenous mRNA vaccine; more stable than many mRNA vaccines (no ultra-cold storage) |
| iNCOVACC | Bharat Biotech | Adenovirus-vectored | World’s FIRST intranasal COVID-19 booster |
India’s Vaccine Diplomacy — ‘Vaccine Maitri’
Vaccine Maitri (Vaccine Friendship) is India’s strategic humanitarian initiative launched during the COVID-19 pandemic — a shining example of vaccine diplomacy. It reflects India’s role as the ‘Pharmacy of the World’.
- Scale: ~298 million doses delivered to ~100 countries through grants, commercial exports, and COVAX.
- Beneficiaries: Nepal, Bhutan, Bangladesh, Sri Lanka, African countries, small island states (Fiji, Mauritius).
- Soft power: Reinforced India’s global goodwill, especially among the Global South.
- Supported by: Serum Institute of India (Covishield) and Bharat Biotech (Covaxin).
India’s Immunisation Programmes
Universal Immunisation Programme (UIP)
The UIP is India’s flagship public health programme providing free vaccination against life-threatening diseases. It was launched as the Expanded Programme on Immunisation (EPI) in 1978 and renamed Universal Immunisation Programme (UIP) in 1985. It is one of the world’s largest public health programmes.
Read in Detail here
Mission Indradhanush
Mission Indradhanush was launched by the Ministry of Health and Family Welfare (MoHFW) in 2014. It is a special catch-up campaign under UIP, targeting the same 12 vaccine-preventable diseases.
Its goal: at least 90% of children and pregnant women fully immunised.
It specifically targets children under 2 years and pregnant women in urban slums, tribal areas, nomadic populations, and conflict-affected zones — the most vulnerable and hardest to reach.
Read in Detail here
Gene Therapy
Consider this: most conventional medicines treat the symptoms of a disease. Gene therapy goes further — it attempts to fix the root cause at the level of the gene itself. It is a biotechnology-based technique used to treat or prevent diseases by modifying, replacing, or introducing genes in a patient’s cells.
Methods of Gene Therapy
- Gene Replacement: A functional copy of a defective gene is inserted to restore normal function.
- Gene Inactivation: A harmful or overactive gene is silenced.
- Gene Editing: Genes are corrected using tools like CRISPR-Cas9.
Gene Delivery Systems (Vectors)
Genes cannot enter cells on their own — they need ‘vehicles’ called vectors.
| Vector Type | Method | Examples |
| Viral Vectors | Genetically modified viruses (disease-causing parts removed) used to deliver therapeutic genes | Adenovirus, Retrovirus, Lentivirus |
| Liposomes | Lipid vesicles that encapsulate DNA and facilitate entry into cells | Non-viral; lipid-based |
| Nanoparticles | Nanoscale carriers that transport genetic material into target cells | Non-viral; nanotechnology-based |
| Direct DNA Injection | Naked DNA is injected directly into target tissues | Non-viral; simple method |
| Electroporation | Electrical pulses temporarily create pores in cell membranes allowing DNA entry | Non-viral; physical technique |
Types of Gene Therapy
| Type | Cells Targeted | Inheritance? | Ethical Status |
| Somatic Gene Therapy | Somatic (body) cells | No — affects only treated individual | Most widely used; ethically accepted |
| Germline Gene Therapy | Germ cells (sperm, eggs, early embryos) | YES — changes inherited by future generations | Generally prohibited in humans due to ethical, safety & regulatory concerns |
Medical Applications of Gene Therapy
- Genetic Disorders: Sickle cell disease, cystic fibrosis, haemophilia.
- Cancer Treatment: Destroy cancer cells or enhance immune response — e.g., CAR-T cell therapy.
- Infectious Diseases: Block viral replication — COVID-19, Ebola treatments explored.
- Neurological Disorders: Spinal muscular atrophy, Parkinson’s disease (under research).
- Eye Disorders: Leber congenital amaurosis — inherited blindness treated successfully.
Cell-Based Therapies
Cell-based therapies are medical treatments in which living cells are introduced into a patient’s body to repair, replace, or regenerate damaged tissues and treat diseases. Cells may be from the patient themselves (autologous) or from a donor (allogeneic).
| Type | What It Does | Examples |
| Stem Cell Therapy | Uses stem cells that can differentiate into specialised cell types to repair or regenerate damaged tissues | Blood disorders (leukaemia, aplastic anaemia), tissue regeneration |
| Immune Cell Therapy | Modifies/activates immune cells to fight diseases — especially cancer | CAR-T cell therapy |
| Tissue Engineering | Combines living cells with biomaterials/scaffolds to create functional tissues | Skin regeneration (burns), bone/cartilage repair |
| Cell Transplantation | Transfers healthy cells to replace/restore function of diseased cells | Bone marrow transplantation for blood disorders |
CAR-T Cell Therapy
Imagine if we could take your own immune cells, send them to a ‘training academy’ where they are genetically programmed to recognise and destroy cancer cells, then send them back into your body as an elite anti-cancer force. That is, in essence, CAR-T Cell Therapy — Chimeric Antigen Receptor T-cell Therapy.
It is a form of personalised immunotherapy where a patient’s T-cells (white blood cells that fight infections) are genetically engineered to express Chimeric Antigen Receptors (CARs) that recognise and attack cancer cells.
How CAR-T Cell Therapy Works — Step by Step
STEP 1 T-CELL COLLECTION (Leukapheresis) — Blood drawn from patient; T-cells separated and collected.
↓
STEP 2 GENETIC ENGINEERING — T-cells genetically modified by inserting CAR genes using a viral vector (lentivirus/retrovirus) or CRISPR-Cas9. CARs on cell surface now recognise specific cancer cell antigens (e.g., CD19).
↓
STEP 3 CELL MULTIPLICATION — Modified T-cells grown in millions to billions in the lab.
↓
STEP 4 INFUSION INTO PATIENT — Engineered CAR-T cells infused back into patient’s bloodstream.
↓
STEP 5 TARGET & KILL — CAR-T cells circulate, locate cancer cells expressing the target antigen (CD19 for B-cell cancers), bind to them, and destroy them.
Benefits vs. Challenges of CAR-T Cell Therapy
| Benefits | Challenges / Concerns |
| Highly targeted — minimal damage to healthy tissues | Cytokine Release Syndrome (CRS) — dangerous immune overreaction (fever, low BP, multi-organ failure) |
| Effective in relapsed/refractory blood cancers (B-cell leukaemia, lymphoma) | Neurotoxicity — confusion, seizures, rarely coma |
| Long-term protection via memory T-cells | Very high cost — globally ₹3–4 crore; even NexCAR19 costs ₹30–40 lakh |
| Personalised — uses patient’s own cells (minimal rejection risk) | Complex manufacturing — 2–4 weeks; needs specialised facilities and staff |
| Fewer infusions needed (1–2) vs. repeated chemo cycles | Limited success in solid tumours — dense microenvironment and lack of specific antigens |
| Potential to revolutionise cancer care | Risk of relapse via antigen escape (cancer cells lose CD19 to evade detection) |
NexCAR19 — India’s Indigenous CAR-T Therapy
NexCAR19 is India’s first indigenously developed CAR-T cell therapy, created to treat B-cell cancers (leukaemias and lymphomas). It was developed by ImmunoACT, a startup incubated at IIT Bombay in collaboration with Tata Memorial Centre.
- Mechanism: Modifies patient’s T-cells to target CD19 — a protein on many B-cell cancers.
- Status: Market authorisation from CDSCO — approved for relapsed/refractory B-cell lymphomas and leukaemias.
- Significance: At ~₹30–40 lakh vs. global cost of ~₹3–4 crore, it is 1/10th the international price — dramatically improving accessibility for Indian patients and reducing medical tourism.
Stem Cell Therapy
Think of stem cells as the master cells of the human body — undifferentiated cells that have two extraordinary abilities: they can self-renew (produce more stem cells) and differentiate (become any specialised cell — muscle, nerve, blood). Stem Cell Therapy uses these cells to repair, replace, or regenerate damaged tissues and organs.
Types of Stem Cells Used in Therapy
| Type | Source | Potency | Key Feature |
| Adult Stem Cells (Somatic) | Bone marrow, fat, skin | Multipotent — limited range of cell types | E.g., blood stem cells → RBCs, WBCs, platelets |
| Embryonic Stem Cells (ESCs) | 5–7 day old embryos (blastocyst) | Pluripotent — can become ANY cell type | Most powerful, but raises ethical concerns (embryo destruction) |
| Induced Pluripotent Stem Cells (iPSCs) | Adult cells (e.g., skin) genetically reprogrammed | Pluripotent — can form any cell type | Bypasses embryo ethics; Nobel Prize-winning discovery (Yamanaka, 2012) |
| Perinatal Stem Cells | Umbilical cord blood or placenta after birth | Multipotent | Mainly used for blood and immune-related treatments |
Applications of Stem Cell Therapy
- Blood & Immune Disorders: Bone marrow transplants for leukaemia, lymphoma, thalassaemia, sickle cell anaemia, and severe lupus.
- Neurological Disorders: Early trials for Parkinson’s disease, spinal cord injuries, multiple sclerosis, stroke recovery.
- Cardiovascular: Regenerate damaged heart muscle after heart attacks.
- Eye Diseases: Repair cornea/retina — macular degeneration, corneal blindness.
- Bone & Cartilage Repair: Mesenchymal stem cells for osteoarthritis and bone fractures.
- Diabetes: Create insulin-producing beta cells to replace damaged pancreas cells in Type 1 diabetes.
- Drug Testing: Lab-grown stem cell-derived tissues for safer drug testing before human trials.
- Skin Treatment: Stem cell skin grafts for severe burns or chronic ulcers.
- Organ Regeneration (Future): Long-term goal — grow new organs from patient’s own stem cells, eliminating transplant waitlists.
Challenges of Stem Cell Therapy
- Risk of tumours: Pluripotent cells (ESCs/iPSCs) can form teratomas if not adequately controlled.
- Immune rejection: Non-matched transplanted cells may be rejected by the immune system.
- Ethical & moral issues: Embryonic stem cells require embryo destruction — serious ethical and religious debate.
- High cost & technical complexity: Advanced labs, skilled personnel, strict quality control.
- Genetic instability: Lab-expanded cells may accumulate mutations.
- Regulatory challenges: Strict laws, standardisation, and long-term monitoring remain global challenges.
Molecular Diagnostics
Traditional diagnosis depends on symptoms and clinical tests. Molecular diagnostics goes deeper — it analyses DNA, RNA, or proteins at the molecular level to identify genetic mutations, pathogens, or biomarkers before symptoms even appear. It is the science of reading the body’s own biological text.
| Technique | What It Does | Applications |
| Polymerase Chain Reaction (PCR) | Amplifies specific DNA sequences — detects tiny amounts of genetic material | Detection of pathogens (COVID-19, TB); identifying genetic mutations |
| DNA Sequencing | Determines exact order of nucleotides (A, T, G, C) in a DNA molecule | Diagnosis of genetic/inherited disorders; cancer mutation detection |
| DNA Microarray | Analyses thousands of genes simultaneously for expression patterns and variations | Genetic research; identifying gene expression patterns in cancers |
| Fluorescence In Situ Hybridisation (FISH) | Uses fluorescent DNA probes to detect specific DNA sequences on chromosomes | Detection of chromosomal abnormalities; diagnosis of genetic disorders and cancers |
Advantages & Disadvantages
| Advantages | Disadvantages |
| High sensitivity & specificity — detects very small amounts of genetic material | High cost — advanced instruments and reagents are expensive |
| Early disease detection — before symptoms appear | Risk of contamination — PCR’s sensitivity can cause false positives |
| Rapid & accurate results | Ethical/privacy concerns — genetic data privacy, discrimination, misuse |
| Supports personalised medicine — tailored treatment | Requires specialised infrastructure and expertise |
Pharmacogenomics and Personalised Medicine
Have you wondered why the same medicine works brilliantly for one person and causes serious side effects in another? The answer lies in our genes. Pharmacogenomics is the study of how an individual’s genetic makeup influences their response to drugs. It combines Pharmacology + Genomics to determine the right drug, right dose, right patient.
Personalised Medicine (Precision Medicine) is the broader approach — tailoring treatments to an individual’s genetic, environmental, and lifestyle factors. Pharmacogenomics is a key component of this.
| Advantages | Disadvantages |
| Improved drug effectiveness — treatments tailored to genetic profile | High cost — genomic analysis and targeted treatments are expensive |
| Reduced adverse drug reactions — avoid harmful medications | Ethical/privacy concerns — genetic data privacy and discrimination |
| Optimised dosage — right dose for each patient | Limited availability — needs advanced labs and trained professionals |
| Better disease prevention — identify high-risk individuals early | Complex data interpretation — needs specialised expertise |
| Reduced trial-and-error prescribing |
Biosimilars
When a conventional drug’s patent expires, a generic drug can be made — it is chemically identical to the original. But biopharmaceuticals are made by living cells — you cannot make an exact identical copy. The closest you can get is a biosimilar — a biological medicine that is highly similar (not identical) to the original biologic in quality, safety, and efficacy, developed after the original’s patent expires.
| Feature | Biosimilars | Generic Drugs |
| Drug Type | Biologic medicines | Conventional chemical drugs |
| Molecular Complexity | Large and complex molecules | Small simple molecules |
| Similarity | Highly similar but NOT identical | Identical to the original drug |
| Manufacturing | Produced using living cells | Produced by chemical synthesis |
| Regulatory Testing | Extensive comparability studies required | Relatively simpler approval process |
Advantages & Disadvantages of Biosimilars
| Advantages | Disadvantages |
| Lower cost — more affordable than original biologics | Complex manufacturing — difficult and expensive to produce |
| Improved patient access, especially for chronic diseases | Not identical to original biologic — exact replication impossible |
| Promotes market competition — further reduces prices | Extensive regulatory requirements — lengthy development |
| Comparable clinical effectiveness to reference biologic | Risk of immunogenic reactions from minor structural variations |
| Supports healthcare sustainability | Limited interchangeability — switching needs medical supervision |
Bioinformatics
The Human Genome Project generated petabytes of data on human DNA. Making sense of this enormous biological data requires computers, mathematics, and statistics. Bioinformatics is the interdisciplinary field that brings these together to collect, store, analyse, and interpret biological data — especially DNA, RNA, and protein sequences.
Major Components of Bioinformatics
- Biological Databases: Store massive biological information — DNA sequences, protein structures, gene expression data.
- Sequence Analysis: Compare and analyse DNA/RNA/protein sequences computationally.
- Structural Bioinformatics: Study 3D structures of proteins and nucleic acids using computational methods.
- Genomics & Proteomics Analysis: Analyse entire genomes and protein networks.
Major Applications of Bioinformatics in Medicine
| Application | What It Does |
| Genome Analysis | Identify disease-related genes and mutations; detect genetic disorders; understand gene functions |
| Drug Discovery & Development | Identify drug targets; design new drugs; structure-based drug design; screen potential molecules computationally |
| Disease Diagnosis | Analyse genetic/molecular data to diagnose diseases; identify biomarkers; detect cancer mutations |
| Personalised Medicine | Tailor treatments based on genetic profiles; predict drug responses and side effects |
| Vaccine Development | Identify antigenic proteins; design recombinant and mRNA vaccines; analyse viral genomes during outbreaks |
Ethical & Regulatory Issues in Health Biotechnology
Ethical Issues
- Genetic privacy: Genetic testing generates sensitive data. Concerns about storage, privacy, and misuse.
- Genetic discrimination: Risk of discrimination in employment or insurance based on genetic predispositions.
- Germline gene editing: Editing germ cells risks heritable changes, ‘designer babies’, and unknown long-term genetic impacts. Generally prohibited.
- Stem cell research ethics: Use of embryonic stem cells requires embryo destruction — serious ethical and religious debate.
- Equity and access: Expensive biotech treatments may widen healthcare gaps between rich and poor.
- Clinical trial ethics: Human trials require ethical transparency, informed consent, and strict oversight — especially in low-income countries.
Regulatory Issues
- Safety & clinical trials: Strict evaluations required before approval.
- Regulation of biopharmaceuticals: Regulatory agencies assess quality, safety, and efficacy before marketing.
- Biosafety regulations: Research involving GMOs or recombinant DNA must follow biosafety guidelines.
- Intellectual Property Rights (IPR): Patents on genes, drugs, or technologies raise questions about access and affordability.
Regulation of Biotechnology Drugs in India
Key Regulatory Authorities
| Authority | Role |
| Central Drugs Standard Control Organisation (CDSCO) | India’s national regulatory authority under MoHFW, headed by DCGI — approves biotech drugs/vaccines, regulates clinical trials, monitors pharmacovigilance |
| Indian Council of Medical Research (ICMR) | Develops ethical guidelines for biomedical research (gene therapy, stem cells, genetic testing); oversees clinical trial ethics and participant safety |
Major Laws Governing Biotechnology Drugs in India
| Law / Act | Key Provision |
| Drugs & Cosmetics Act, 1940 | Primary legislation for manufacture, import, distribution, and sale of drugs in India; biotech drugs require DCGI approval; establishes drug quality and clinical trial standards |
| Drugs & Cosmetics Rules, 1945 | Detailed procedures for licensing, manufacturing, labelling, and clinical trials; specific provisions for biologics, vaccines, and biopharmaceuticals |
| Environment (Protection) Act, 1986 | Regulates activities involving GMOs and biotech products; provides legal framework for biosafety regulations |
| Rules for GMOs/Cells, 1989 | Issued under Environment Protection Act; governs R&D, production, handling, import, export, and environmental release of GMOs in biotechnology |
| New Drugs & Clinical Trials Rules, 2019 | Regulatory framework for new drug approval, clinical trials, and bioequivalence studies; includes specific provisions for biotech-derived products |